NO943915D0 - Lymfocyt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien - Google Patents
Lymfocyt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilienInfo
- Publication number
- NO943915D0 NO943915D0 NO943915A NO943915A NO943915D0 NO 943915 D0 NO943915 D0 NO 943915D0 NO 943915 A NO943915 A NO 943915A NO 943915 A NO943915 A NO 943915A NO 943915 D0 NO943915 D0 NO 943915D0
- Authority
- NO
- Norway
- Prior art keywords
- lymphocyte activation
- activation antigen
- immunoglobulin superfamily
- disclosed
- expressed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/870,029 US5316920A (en) | 1992-04-17 | 1992-04-17 | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily |
PCT/US1993/003577 WO1993021318A1 (en) | 1992-04-17 | 1993-04-14 | Lymphocyte activation antigen hb15, a member of the immunoglobulin superfamily |
Publications (2)
Publication Number | Publication Date |
---|---|
NO943915D0 true NO943915D0 (no) | 1994-10-14 |
NO943915L NO943915L (no) | 1994-12-09 |
Family
ID=25354648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO943915A NO943915L (no) | 1992-04-17 | 1994-10-14 | Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien |
Country Status (10)
Country | Link |
---|---|
US (1) | US5316920A (no) |
EP (1) | EP0636176B1 (no) |
JP (2) | JP3973167B2 (no) |
AT (1) | ATE185600T1 (no) |
AU (1) | AU685745B2 (no) |
BR (1) | BR9306344A (no) |
CA (1) | CA2118309C (no) |
DE (1) | DE69326759T2 (no) |
NO (1) | NO943915L (no) |
WO (1) | WO1993021318A1 (no) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5710262A (en) * | 1992-04-17 | 1998-01-20 | Dana-Faber Cancer Institute, Inc. | Nucleic acid encoding HB15 polypeptides |
US5534430A (en) * | 1993-08-31 | 1996-07-09 | Hitachi Chemical Company Limited | Cell strain capable of multiplying an Epstein-Barr virus |
WO1997029781A1 (en) * | 1996-02-15 | 1997-08-21 | Immunex Corporation | Methods and compositions for modulating an immune response |
US5849589A (en) * | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
AU5356498A (en) * | 1996-11-27 | 1998-06-22 | Schering Corporation | Isolated mammalian dendritic cell genes; related reagents |
US6361939B1 (en) | 1996-11-27 | 2002-03-26 | Schering Corporation | Isolated mammalian dendritic cell genes; related reagents |
US6228640B1 (en) | 1997-02-07 | 2001-05-08 | Cem Cezayirli | Programmable antigen presenting cell of CD34 lineage |
US6251665B1 (en) | 1997-02-07 | 2001-06-26 | Cem Cezayirli | Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom |
US6977073B1 (en) | 1997-02-07 | 2005-12-20 | Cem Cezayirli | Method for stimulating an immune response |
US7229621B2 (en) | 1998-10-20 | 2007-06-12 | Torrey Pines Institute For Molecular Studies | Method to enhance the immunogenicity of an antigen |
US6210672B1 (en) | 1998-10-20 | 2001-04-03 | Torrey Pines Institute For Molecular Studies | Topical immunostimulation to induce Langerhans cell migration |
GB2370273A (en) * | 2000-12-20 | 2002-06-26 | Viaxxel Biotech Gmbh | Compounds that affect CD83 expression |
WO2003045318A2 (en) * | 2001-11-21 | 2003-06-05 | Celltech R & D, Inc. | Manipulation of cytokine levels using cd83 gene products |
US20040185040A1 (en) * | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
AU2002950779A0 (en) * | 2002-08-15 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of immunomodulation |
EP1422241A1 (en) | 2002-11-19 | 2004-05-26 | Alexander Steinkasserer | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
EP1572976B1 (en) | 2002-11-21 | 2010-09-15 | Celltech R & D, Inc. | Modulating immune responses |
US9102726B2 (en) * | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
US7169898B2 (en) * | 2002-12-04 | 2007-01-30 | Alexander Steinkasserer | Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells |
US20140010821A1 (en) | 2006-08-18 | 2014-01-09 | Aili Lao | Use of CD83 in combination therapies |
CN103546228B (zh) | 2007-06-15 | 2017-08-08 | 光学无线技术有限责任公司 | 无线通信装置、响应信号扩频方法以及集成电路 |
KR101679084B1 (ko) * | 2008-05-23 | 2016-11-24 | 아고스 쎄라퓨틱스, 인코포레이티드 | 신규 가용성 cd83 폴리펩티드, 제형 및 사용 방법 |
JP6539585B2 (ja) | 2013-02-01 | 2019-07-03 | デンドロサイト バイオテック ピーティーワイ リミテッド | 抗cd83抗体及びその使用 |
AU2015336931B2 (en) | 2014-10-23 | 2021-04-29 | Kira Biotech Pty Limited | CD83 binding proteins and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2010321C (en) * | 1989-02-21 | 2004-04-06 | Thomas F. Tedder | Lymphocyte-associated cell surface protein |
FR2656800B1 (fr) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
CA2087272C (en) * | 1990-07-13 | 2005-10-11 | Brian Seed | Cd53 cell surface antigen and use thereof |
-
1992
- 1992-04-17 US US07/870,029 patent/US5316920A/en not_active Expired - Lifetime
-
1993
- 1993-04-14 DE DE69326759T patent/DE69326759T2/de not_active Expired - Lifetime
- 1993-04-14 AU AU41048/93A patent/AU685745B2/en not_active Expired
- 1993-04-14 BR BR9306344A patent/BR9306344A/pt not_active Application Discontinuation
- 1993-04-14 EP EP93910619A patent/EP0636176B1/en not_active Expired - Lifetime
- 1993-04-14 CA CA002118309A patent/CA2118309C/en not_active Expired - Lifetime
- 1993-04-14 JP JP51862093A patent/JP3973167B2/ja not_active Expired - Lifetime
- 1993-04-14 WO PCT/US1993/003577 patent/WO1993021318A1/en active IP Right Grant
- 1993-04-14 AT AT93910619T patent/ATE185600T1/de not_active IP Right Cessation
-
1994
- 1994-10-14 NO NO943915A patent/NO943915L/no unknown
-
2006
- 2006-12-07 JP JP2006330466A patent/JP2007159580A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU4104893A (en) | 1993-11-18 |
WO1993021318A1 (en) | 1993-10-28 |
DE69326759T2 (de) | 2000-03-02 |
JP2007159580A (ja) | 2007-06-28 |
BR9306344A (pt) | 1998-06-30 |
CA2118309C (en) | 2000-06-13 |
DE69326759D1 (de) | 1999-11-18 |
CA2118309A1 (en) | 1993-10-28 |
NO943915L (no) | 1994-12-09 |
US5316920A (en) | 1994-05-31 |
AU685745B2 (en) | 1998-01-29 |
JP3973167B2 (ja) | 2007-09-12 |
JPH09508781A (ja) | 1997-09-09 |
ATE185600T1 (de) | 1999-10-15 |
EP0636176B1 (en) | 1999-10-13 |
EP0636176A1 (en) | 1995-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO943915D0 (no) | Lymfocyt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien | |
Germann et al. | Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells | |
Vercelli et al. | Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens. | |
Seeley et al. | Studies on Cytotoxicity Generated in Human Mixed Lymphocyte Cultures: II. Anti-K562 Effectors Are Distinct from Allospecific CTL and Can Be Generated from NK-Depleted T Cells | |
AU2349697A (en) | Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon | |
Funk et al. | Helium‐neon laser irradiation induces effects on cytokine production at the protein and the mRNA level | |
DK0751992T3 (da) | Karendotelvækstfaktor 2 | |
EE03285B1 (et) | Immuunsust stimuleerivad monoklonaalsed antikehad | |
DK0489837T4 (da) | Inhibering af lymfocytters adhæsion til vaskulært endotel under anvendelse af en hidtil ukendt interaktion mellem ekstracellulær matrixreceptor og ligand | |
Klaus et al. | A re-evaluation of the role of C3 in B-cell activation | |
EP1003552A4 (en) | ANTIBODIES DIRECTED AGAINST LO-CD2a AND USE THEREOF TO INHIBIT THE ACTIVATION AND PROLIFERATION OF T-LYMPHOCYTES | |
DE69333076D1 (de) | Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis | |
Samberg et al. | Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes | |
Schwab et al. | Defective expression of high affinity IL-2 receptors on activated T cells from aged humans | |
Hodge et al. | Effect of factor VIII concentrate on leucocyte cytokine production: characterization of TGF‐beta as an immunomodulatory component in plasma‐derived factor VIII concentrate | |
Yoshino | Effect of a monoclonal antibody against interleukin‐4 on collagen‐induced arthritis in mice | |
NO862097L (no) | Monoklonale antistoffer for humane ikke-smaacelle lungekarsinoma. | |
De Weck et al. | New perspectives in the modulation of allergic inflammation | |
Butcher et al. | Flow cytometric studies of IL-4-stimulated expression of the CD25 antigen by quiescent human B lymphocyte subpopulations. | |
Pollack et al. | Inhibition of antibody-dependent cellular cytotoxicity by autologous lymph node cells | |
Poros et al. | Expression of Helix pomatia (HP) haemagglutinin receptors on cytolytic lymphocytes activated in mixed cultures | |
HK1021318A1 (en) | Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation | |
Ezine et al. | Haemopoiesis and early T-cell differentiation | |
Mosmann et al. | Heterogeneity of mouse helper T cells and cross-regulation of TH1 and TH2 clones | |
Gorczynski et al. | Individual‐specific (idiotypic) T‐B cell interactions regulating the production of anti‐2, 4, 6‐trinitrophenyl antibody. I. Generation of suppressor T cells and antibody directed against immunocompetent cells |